Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;21(32):2890-2908.
doi: 10.2174/1568026621666211116090917.

Carbon Monoxide as a Therapeutic for Airway Diseases: Contrast and Comparison of Various CO Delivery Modalities

Ravi Tripathi  1 , Xiaoxiao Yang  1 , Stefan W Ryter  2 , Binghe Wang  1
Affiliations
Review

Carbon Monoxide as a Therapeutic for Airway Diseases: Contrast and Comparison of Various CO Delivery Modalities

Ravi Tripathi et al. Curr Top Med Chem. 2021.

Abstract

The quest to find novel strategies to tackle respiratory illnesses has led to the exploration of the potential therapeutic effects of carbon monoxide (CO) as an endogenous signaling molecule and a cytoprotective agent. Further, several studies have demonstrated the pharmacological efficacy of CO in animal models of respiratory disorders, such as acute lung injury and pulmonary hypertension. Because of the gaseous nature of CO and its affinity for multiple targets, its controlled delivery has been a challenge. Past studies have employed different delivery modalities, including CO gas, HO-1 inducers, and CO donors, sometimes leading to substantive variations in the resulting pharmacological effects for various reasons. Herein, this review summarizes and analyzes the differences among the profiles of various CO-delivery modalities in terms of their efficacy, dosing regimen, and pharmacokinetics in airways models. We believe that analysis of these issues will help in understanding the fundamental roles of CO in airways, and eventually, contribute to its development as a medicine for respiratory diseases.

Keywords: CO; CO-RMs; Cytokines; Delivery modalities.; HO-1 inducers; Respiratory system.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest declaration: Stefan Ryter holds interests in Proterris, a company focused on developing CO-based therapeutics.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wu L; Wang R, Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 2005, 57, 585–630. - PubMed
    1. Yang X-X; Ke B-W; Lu W; Wang B-H, CO as a therapeutic agent: discovery and delivery forms. Chin J Nat Med 2020, 18 (4), 284–295. - PubMed
    1. Hopper CP; De La Cruz LK; Lyles KV; Wareham LK; Gilbert JA; Eichenbaum Z; Magierowski M; Poole RK; Wollborn J; Wang B, Role of Carbon Monoxide in Host–Gut Microbiome Communication. Chem Rev 2020, 120 (24), 13273–13311. - PubMed
    1. Yang X; de Caestecker M; Otterbein LE; Wang B, Carbon monoxide: An emerging therapy for acute kidney injury. Med Res Rev 2020, 40 (4), 1147–1177. - PMC - PubMed
    1. Hart CL; Smith GD; Hole DJ; Hawthorne VM, Carboxyhaemoglobin concentration, smoking habit, and mortality in 25 years in the Renfrew/Paisley prospective cohort study. Heart 2006, 92, 321–4. - PMC - PubMed

MeSH terms

Substances